Our previous study found that MYB is overexpressed in clinical MDS samples compared with normal samples and that MYB regulates MDS-L and SKM-1 cell viability via PI3K-AKT pathway [4, 34]. This evidence concerns the gene MYB and myelodysplastic syndrome.